Sentence examples for bone disease compared to from inspiring English sources
The table includes information on gene symbol, protein identification, measured peptides (used for quantitation), confidence score (MASCOT), Benjamini-Hochberg adjusted p-value and fold-change (- indicates a protein is decreased in abundance in no bone disease compared to high bone disease, all other proteins are increased in abundance in no bone disease compared to high bone disease).
Paricalcitol resulted also bone protective in experimental models compared to vehicle [ 73] and with a lower risk of adynamic bone disease compared to calcitriol [ 74], doxercalciferol [ 75], or cinacalcet [ 38].
Dkk-1 levels at baseline were increased both in the study population compared to the control groups and in the MM patients with high of bone disease compared to all other groups [ 119].
It was observed that complement factor H-related protein 1 and complement C1s subcomponent were present at lower concentrations in the patients with high bone disease compared to no bone disease.
Our discovery phase results demonstrate a significant elevation in the concentrations of both VTN and FN1 in high bone disease compared to no bone disease patient samples, suggesting that these proteins are released into the circulation due to increased bone resorption related to stimulation of osteoclast formation and activity.
The categories for PSA were selected based upon previous findings that patients with PSA greater than 20 ng ml−1 have a high risk and patients with PSA greater than100 ng ml−1 have a very high risk of bone metastatic disease compared to those with PSA less than 20 ng ml−1 (Oesterling, 1991; Rana et al, 1992).
This finding confirms the report of Jodar et al (1997) and Belaya et al (2007), they found no difference in bone mineral density in patients with Graves' disease compared to those with toxic multinodular goiter [ 7, 34].
The cost of treatment among prostate and breast cancer patient of lower disease compared to those of higher stages, positive bone metastasis and SRE positive.
Therefore, the frequency of ONJ appears to be lower among patients with no malignant bone disease compared with patients who have advanced cancer (Mavrokokki et al 2007).
The large phase III trials in metastatic bone disease comparing denosumab with zoledronic acid have completed accrual and will report in the next year.
